EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) AND P53, BCL-2 OR C-ERB B-2 PROTEINS ON REED-STERNBERG CELLS - PROGNOSTIC-SIGNIFICANCE IN HODGKINS-DISEASE

Citation
P. Smolewski et al., EXPRESSION OF PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) AND P53, BCL-2 OR C-ERB B-2 PROTEINS ON REED-STERNBERG CELLS - PROGNOSTIC-SIGNIFICANCE IN HODGKINS-DISEASE, Neoplasma, 45(3), 1998, pp. 140-147
Citations number
28
Categorie Soggetti
Oncology
Journal title
ISSN journal
00282685
Volume
45
Issue
3
Year of publication
1998
Pages
140 - 147
Database
ISI
SICI code
0028-2685(1998)45:3<140:EOPCNA>2.0.ZU;2-0
Abstract
Expression of proliferating cell nuclear antigen (PCNA) as well as p53 , bcl-2 and C-erb B-2 genes protein products on Reed-Sternberg/Hodgkin 's (R-S/H) cells was analyzed by immunohistochemistry in 65 patients w ith Hodgkin's disease CHD). Their significance as markers of clinical malignancy and prognostic factors was evaluated. Positive reaction for PCNA was present in 57 cases (87.7%), for p53 in 42 (64.6%), for bcl- 2 in 41 (63.1%), and for Cerb B-2 in 38 cases (58.5%) of HD. The high proliferate PCNA index and high expression of p53 and bcl-2 correlated with poor response to the treatment. Expression of both p53 and bcl-2 oncoproteins negatively influenced overall survival and disease free survival. Indexes of PCNA, p53 and bcl-2 were significantly higher in patients with advanced disease then in early clinical stages. In LP ty pe of HD the lowest indexes of PCNA or bcl-2 and even lack of bcl-2 ex pression on R-S/H cells were observed. There was no correlation betwee n expression of C-erb B-2 and response to the treatment, time of survi val, clinical stage or histopathological types of HD. Statistical anal ysis let us to the conclusion, that indexes of PCNA, p53 and bcl-2 exp ression can be taken into consideration as a new prognostic factors in Hodgkin's disease. C-erb B-2 protein expression seems to be of no val ue for prognosis in HD.